We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Btg Plc | LSE:BTG | London | Ordinary Share | GB0001001592 | ORD 10P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 840.00 | 839.00 | 840.00 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
28/4/2017 07:47 | You must be right nervous novice . May be better taking an average of the three which is 37.66. Still high for a non divi company with a track record of not delivering growth as forecast. Hopefully that is about to change. | bargainbob | |
28/4/2017 01:57 | well it shows as 30 on HL | nervousnovice | |
27/4/2017 23:41 | 43 on today's listing on the financials link. | fhmktg | |
27/4/2017 18:23 | Not 40x PE it is 30 and that will change substantively when the results are out. | nervousnovice | |
27/4/2017 17:44 | No divi , 40 times PE , not a lot of value . | bargainbob | |
27/4/2017 16:36 | Bargain bob , rising turover , rising profits per coming down , dollar doing well , this is good for steady rise | doctor 69 | |
27/4/2017 16:20 | looks good for a close above the resistance line today | nervousnovice | |
27/4/2017 07:35 | Hope it not just Woodford , pretty sure he is behind the large swings in BTG every year. Would love it to be other large shareholders . From what I can see not a lot of value for anyone buying at the moment , unless a takeover is on the cards . | bargainbob | |
27/4/2017 01:09 | Woodford bought Allied Minds and look what happened there, I hope he isn't bringing the kiss of death! Seems to have broken through the resistance line hopefully it can hold out and move higher tomorrow. | nervousnovice | |
26/4/2017 23:28 | Rns 13/4/17 stake now over 10% Close relationship with Louise Whatch out for more holdings updates. | dp1umb | |
26/4/2017 19:53 | Could be results leakage and shorts closing perhaps | cyman | |
26/4/2017 19:23 | Dp is that a guess or you seen it somewhere? | cyman | |
26/4/2017 19:23 | DP1 Is that speculation or fact? | nervousnovice | |
26/4/2017 17:22 | No Woodford buying a bigger stake! | dp1umb | |
26/4/2017 17:13 | I bought this more years ago then I can remember , something is very much up. Takeover at last ? | bargainbob | |
26/4/2017 15:39 | Bought in last week and today looks interesting | doctor 69 | |
26/4/2017 14:27 | I bought this a couple of weeks ago expecting the downward trend in place since January 2015 to reverse. A good start, up 9%. We are approaching the all important resistance line, I expect a breakout before or on the results in May, they have indicated results will be at the upper end or above forecasts continuing the growth pattern. | nervousnovice | |
26/4/2017 13:41 | I love this stock and all who sail in her.Assisted by some barbed criticism here,I've had a damascene experience! | steeplejack | |
26/4/2017 13:08 | wow , bit of a kick today. | bargainbob | |
25/4/2017 12:29 | Do not know much , looks like a useful tool to influence enhanced treatment for patients . Firstly great if it helps patients with this terrible illness , seconadary an important step if BTG can manage drugs and other treaments in an efficient manner . I suspect this will led to other bolt ons in this sector , may even led to partnerships . A win Win . | bargainbob | |
25/4/2017 12:03 | Any thoughts as to how Oncoverse will enhance the btg group? | fhmktg | |
24/4/2017 16:30 | Impressive turnaround. | revoman | |
24/4/2017 12:45 | Netscientific announces that BTG plc has purchased Wanda's shares in OncoVerse for next stage of development London, UK - 24 April 2017 - NetScientific Plc (AIM: NSCI, "NetScientific", "the Group"), the transatlantic healthcare IP commercialisation Group, announces that its portfolio company Wanda has sold its holding in OncoVerse LLC ('OncoVerse' or 'the Company') to BTG plc ('BTG') for an undisclosed amount. The sale represents a strong return on NetScientific's initial investment and a successful exit from the first downstream application from Wanda, validating Wanda's superior ability to provide support for clinicians. OncoVerse is a digital health platform designed to allow cancer patients' care teams to collaborate and allow clinicians across all disciplines to work together to determine the most effective treatment plan for their patients. OncoVerse was initially conceived by a Dignity Health physician and two administrators, who wanted a tool to improve team collaboration, especially when evaluating complex cancer cases and determining the appropriate treatment plans for patients. Dignity Health, one of the nation's largest health care systems, prototyped and tested the platform internally and then partnered with Wanda to further develop the software. Dignity Health has also been a co-investor in the joint venture since the platform's inception and will continue to be a shareholder alongside BTG. NetScientific's equity in OncoVerse comes from its majority shareholding in Wanda. Commenting on the news, François R. Martelet, Chief Executive Officer of NetScientific and Chairman of Wanda, said: "We believe the OncoVerse platform will become a leading tool in the management of cancer patients and we are proud to have been involved in helping bring it to maturity. The sale of the equity to BTG represents a strong return on NetScientific's initial investment, and underscores Wanda's unique expertise in creating tools which can support informed treatment decisions. We are continuing to work with Wanda to support the company in the development of remote health management tools and sophisticated data analysis and to identify other promising opportunities to maximise investment returns from the technology." Foad Dabiri, CEO of Wanda, commented: "I am very proud of the team at Wanda for creating such a valuable product, in collaboration with Dignity Health, which helps improve quality of care for cancer patients. BTG's expertise and partnership will enable a strong path forward for Oncoverse and its mission. We at Wanda will continue focusing on building modern and innovative clinical solutions to enhance management of care for patients." - Ends - | bargainbob | |
24/4/2017 12:27 | Strange that BTG did not announce the Oncoverse purchase. I wonder how much they paid. On the face of it it's an advantageous action. It'll be nice though if the bad guys were to stop messing about with the share price ... It probably won't be long now. | muffmitz | |
21/4/2017 18:02 | That's moor like it! | dp1umb |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions